Faeth Therapeutics, a healthcare company developing machine learning-driven precision nutrition solutions and therapeutic regimens to treat cancer, announced the appointment of Endocrine Society member Thomas Strack, MD, as chief medical officer.
Strack brings more than 29 years of biopharmaceutical industry and has led all phases of clinical development. Strack previously served as senior vice president, Clinical Development, at Molecular Templates, a publicly traded biopharmaceutical company where he was responsible for first-in-human trials in patients with solid and hematological tumors. He was also vice president, Clinical Development, at Progenics, and an executive at Asubio where was responsible for first-in-human trials targeting CNS diseases. Strack also held executive positions at Takeda, Pfizer, and Eli Lilly and Company.
Strack earned his medical doctorate from the University in Mainz, Germany, where he completed his internal medicine and endocrinology residencies, with additional postdoctoral research at the Hospital for Sick Children in Toronto, Canada. He has authored numerous scientific and clinical publications.
Loading ...